Home > Search Clinical Trials > Psychiatry - General Adult/Mental Health (Depression, Anxiety, Etc.)
Clinical Trials: Psychiatry - General Adult/Mental Health (Depression, Anxiety, Etc.)
IRB No. 16-055-2 (Dr. David Steffens, PI): Department of Psychiatry: Adult Repository
The purpose of the repository is to prospectively collect biological samples along with clinical data to facilitate future research studies and pilot analysis related to medical and behavioral health research.
IRB No. 20-105-2: Apathy and Biomarkers of Cognitive Decline in Depression Study
This research is being done to determine if older adults who are experiencing depression and/or apathy (decreased motivation) are at increased risk of developing cognitive decline and Alzheimer';s disease. The purpose of this research study is to try and find a better way to diagnosis cognitive decline and/or Alzheimer';s disease in older adults. Diagnosing Alzheimer';s disease or cognitive decline is complex. With no single test currently available, diagnosis is based on an individual';s history, physical examination, and cognitive testing. With the information gathered from a lumbar puncture (or spinal tap) and subsequent analysis of the fluid obtained from the procedure, we may improve our ability to detect brain changes associated with Alzheimer';s disease well before a person begins to experience significant cognitive decline (or dementia).
IRB No. 21-046-2 (Dr. Kevin Manning, PI): Cognitive Remediation of Cognitive Control in Late-Life Depression
This research is being completed because depressed older adults commonly experience difficulties with concentration and processing speed, also called executive dysfunction, as well as negative affect/emotions (e.g., low mood, irritability, worry). Older adults with depression and executive dysfunction and/or negative affect/emotions regularly fail to get better with conventional antidepressant medications. Therefore, the purpose of this study is to use an established non-invasive treatment (computerized brain-training) that may improve cognitive and depression related outcomes in older adults. There are two aims of the current study. We are interested in whether a computerized braintraining treatment will improve thinking and depression in older depressed adults. We are also interested in whether participating in the treatment will result in changes to brain activity measured with magnetic resonance imaging (MRI).
IRB No. O21-071-2 (Dr. Jayesh Kamath, PI): A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression (ESKTRD4005)
This is a clinical research study of an investigational medication for adults with treatment-resistant depression (TRD). The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational medication when it is used alone in adults with TRD. Study participation will last up to 24 weeks and includes a screening phase, a double-blind phase, an open-label/observation phase, and a follow-up phase. Qualified participants may receive investigational study medication and some study-required medical care at no cost.
IRB No. W21-027-2 (Dr. Jayesh Kamath, PI): A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment with Seltorexant
This is a clinical research study of an investigational medication for adults with Major Depressive Disorder (MDD). The purpose of this study is to evaluate its safety and effectiveness when it is used as an adjunct treatment in adults with MDD. Study participation will last up to 12 weeks. In some cases, you may have the option to continue participation for up to an additional 52 weeks. Qualified participants may receive investigational study medication and some study-related medical care at no cost. Participants may receive a stipend for completed in-person visits.
IRB No. 21-257-2 (Dr. Breno Diniz, PI): The SenDep Study: Linking Molecular Senescence Changes to Depression and Cognitive Impairment in Late Life
Late-life depression (LLD) is a common mental disorder in the elderly, with prevalence rates ranging from 1 to 5%. Recent evidence suggests that LLD is linked to age-related negative health outcomes, such as cerebrovascular disease, increased risk of Alzheimer's disease, vascular dementia, and of premature mortality. The mechanisms of LLD are complex and involve the dysregulation of different biological pathways. Understanding the interplay between the biological changes in aging and depression can provide insight into the mechanisms by which LLD increases the risk of negative health outcomes. This study proposes to evaluate the association of Senescence-Associated Secretory Phenotype (SASP) Index with different clinical phenotypes of aging (i.e., cognitive impairment) and with cellular senescence phenotype (i.e., leukocyte telomere [LT] attrition) in LLD. Finally, we will evaluate the trajectory of changes in SASP, and its relationship with cognitive performance in these individuals. Our hypotheses are that LLD individuals will show a significantly higher SASP index compared to age- and gender-matched never-depressed control subjects. SASP index will be significantly associated with greater cognitive impairment and telomere attrition in LLD subjects. We further hypothesize that an increasing or persistently higher SASP index trajectory will lead to faster cognitive decline among study participants over two years of follow-up. To our knowledge, this will be the first study to examine the association between circulating molecular senescence markers (SASP), a cellular senescence marker (LT attrition), and neurocognitive and clinical characteristics in LLD. Based on the results of this study, we will also be able to identify novel targets for the development of interventions aiming not only the treatment of depression in the elderly but also aiming the prevention of the negative outcomes related to this condition